Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
246. |
ECCT/20/09/05 | THE ELLAVI UBT STUDY An investigation into the barriers and facilitators of scaling up the innovative, low-cost Ellavi Uterine Balloon Tamponade for postpartum hemorrhage in Kenya |
Principal Investigator(s) 1. Zahida P Qureshi 2. Omondi Ogutu 3. Alfred Onyango Osoti 4. George Nyakundi Gwako 5. James Soki 6. James Gitonga Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Mbagathi Hospital (Nairobi City county) 3. St. Marys Mission Hospital (Nairobi City county) |
View |
247. |
ECCT/20/07/03 | STAND A Phase III multicenter, randomized, double blind study to assess efficacy and safety of two doses of crizanlizumab verses placebo, with or without hydroxyurea/hydroxycarbamide therapy in adolescent and adult sickle cell disease patients with Vaso-Occlusive Crises (STAND) |
Principal Investigator(s) 1. Bernhards Ragama Ogutu Site(s) in Kenya 1. CREATES Strathmore University (Nairobi City county) 2. Getrudes Childrens Hospital (Nairobi City county) 3. International Cancer Institute (Elgeyo/Marakwet county) |
View |
248. |
ECCT/20/05/02 | COPCOV Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) |
Principal Investigator(s) 1. Anthony Oliwa Etyang Site(s) in Kenya 1. KEMRI - Centre for Geographic Medicine Research Coast (CGMRC) (Kilifi county) 2. KEMRI-Centre for Global Health Research (CGHR) (Kisumu county) |
View |
249. |
ECCT/20/05/01 | ChAdOx1 nCoV-19 trial A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI-CGMRC |
View |
250. |
ECCT/20/04/03 | 518 & 525-SHAN6™ Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants. Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age |
Principal Investigator(s) 1. Bernhards Ogutu 2. Godfrey Allan Otieno 3. Videlis Nduba 4. Lucy Chepkurui Koech 5. samuel Gurrion Ouma 6. Janet Oyieko Site(s) in Kenya 1. Ahero Clinical Trials Unit (Kisumu county) 2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 3. KEMRI Kondele Children’s Hospital (Kisumu county) 4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county) 5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county) 6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county) 7. CRDR_Siaya Annex(Back-up site) (Siaya county) |
View |